Project Grant HT94252410202
Award Date
4/1/24
Completion Date
3/31/28
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
The University of Texas Health Science Center at San Antonio (UTHSCSA) was awarded a $1,116,000 Project Grant by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The award supports a research project titled "ROLE OF PODOCYTE CERAMIDE SYNTHASE 6 IN FSGS" with a performance period from Apr 1, 2024 to Mar 31, 2028. The project aims to investigate the role of a specific protein, ceramide synthase 6, in the development...
The Department of the Army Medical Command awarded $2,449,816 under the Military Medical Research and Development federal grant program (CFDA 12.420) to the University of Nebraska Medical Center for the period of April 1, 2022 through March 31, 2026. The award will support the development of a macromolecular dexamethasone prodrug for the treatment of focal segmental glomerulosclerosis (FSGS). As the sub-awardee, the University of Nebraska Medical Center will leverage its expertise in...
The Department of the Army Medical Command awarded a $472,560 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The funding supports research aimed at "Targeting Mutant Protein Degradation for Therapeutic Intervention of Genetic FSGS", which refers to focal segmental glomerulosclerosis, a type of kidney disease. The grant has a performance period from January 1, 2025 to December...
The federal Project Grant award of $1,640,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research initiatives focused on investigating the therapeutic parameters and mechanism of action of anti-miR-17 drugs in autosomal dominant polycystic kidney disease (ADPKD). The grant was awarded to The University of Texas Southwestern Medical Center, a prominent academic medical center in...
Yale University received a $1,618,571 project grant award from the Defense Health Agency through the Military Medical Research and Development federal grant program (CFDA 12.420). The award will fund research from June 2023 through May 2027 to investigate the role of immune cell-podocyte crosstalk in the pathogenesis of APOL1-FSGS and proteinuric kidney disease. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $2,531,888 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to study "CORRECTING CYTOSKELETAL ABNORMALITIES AND PODOCYTE VULNERABILITY IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS." The 4-year award, starting on May 1, 2024, supports Bidmc's research aimed at improving treatments for this kidney disorder. As a leading academic medical center, Bidmc has an...
The Department of the Army Medical Command awarded a $2,455,660 project grant to Beth Israel Deaconess Medical Center, Inc. (doing business as Bidmc) to support research on "TRANSCRIPTION FACTORS AS THERAPEUTIC TARGETS IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS." The period of performance for this award is from September 30, 2022 through September 29, 2026. The grant is being funded through the Military Medical Research and Development program (CFDA 12.420). This program aims to transform...
The University of Pittsburgh was awarded a $2,077,852 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 2022 through August 2025 to study the pros and cons of NRF2 in focal segmental glomerulosclerosis (FSGS) pathogenesis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
Yale University received a $1,731,409 project grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from June 2023 through May 2027 to investigate the role of immune cell-podocyte crosstalk in the pathogenesis of APOL1-FSGS and proteinuric kidney disease. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
The federal Project Grant award of $1,000,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is supporting research at the Jackson Laboratory in Bar Harbor, Maine to uncover spatial and temporal alterations of metabolism in the kidney, paving the way for treatment of lupus nephritis. The award, effective May 15, 2025 through May 14, 2028, will enable the Jackson Laboratory to conduct advanced biomedical research focused on...